Inegy (Simvastatin, Ezetimibe)

Inegy is used to manage lipid disorders and reduce cardiovascular risk associated with elevated cholesterol levels.

• Hypercholesterolemia: lowers low‑density lipoprotein cholesterol (LDL‑C) to target levels.
• Mixed dyslipidemia: reduces LDL‑C and triglycerides while modestly raising high‑density lipoprotein cholesterol (HDL‑C).
• Primary prevention of cardiovascular disease: helps patients at risk achieve guideline‑recommended lipid goals.

• Inegy combines two agents: simvastatin inhibits HMG‑CoA reductase, decreasing hepatic cholesterol synthesis, while ezetimibe blocks the NPC1L1 transporter in the intestinal brush border, reducing dietary and biliary cholesterol absorption. The dual action produces a greater reduction in circulating LDL‑C than either component alone.

Inegy may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Gastrointestinal discomfort: nausea, abdominal pain, or diarrhoea.
• Myalgia: muscle aches without weakness.
• Elevated liver enzymes: transient increase in ALT/AST.
• Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with risk of renal failure.
• Acute liver injury: marked elevation of hepatic enzymes or jaundice.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Myopathy: muscle weakness with elevated creatine kinase.
• Pancreatitis: abdominal pain with elevated pancreatic enzymes.

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters.

• Liver function monitoring: obtain baseline ALT/AST and repeat periodically.
• Muscle symptom assessment: educate patients to report unexplained muscle pain or weakness.
• Concomitant medication review: avoid strong CYP3A4 inhibitors and certain fibrates.
• Active liver disease: contraindicated in patients with ongoing hepatic impairment.
• Renal impairment: dose adjustment may be required in severe renal dysfunction.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Inegy can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): may increase simvastatin exposure.
• Gemfibrozil or high‑dose fenofibrate: heightened risk of myopathy.
• Niacin (high dose): additive muscle toxicity.
• Cyclosporine: increases both components' plasma concentrations.
• Certain HIV protease inhibitors: elevate simvastatin levels.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in anticoagulant effect.
• Digoxin: may require serum level monitoring.
• Antacids containing aluminum or magnesium: can reduce ezetimibe absorption.
• Grapefruit juice: modest increase in simvastatin exposure.
• Macrolide antibiotics (e.g., erythromycin): may modestly raise simvastatin levels.